Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

Benzinga Newsdesk www.benzinga.com Positive 62.1%

Neg 0% Neu 0% Pos 62.1%

Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.